BTIS
PBYI icon

BB&T Investment Services’s Puma Biotechnology PBYI Stock Holding History

BB&T Investment Services’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$2K Hold
19
– – ﹤0.01% 1277
2017
Q3 		$2K Buy
+19
New +$1.77K ﹤0.01% 1111

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BB&T Investment Services's PBYI Position: Q4 2017 in Review

BB&T Investment Services held its Puma Biotechnology (PBYI) position steady in Q4 2017 at 19 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1277.

BB&T Investment Services first reported a position in PBYI in Q3 2017 and has held it in 2 quarters since. 203 funds tracked by Wall St. Rank hold PBYI as of Q4 2017.

  • BB&T Investment Services held 19 shares of Puma Biotechnology worth $2K as of Q4 2017.
  • BB&T Investment Services left its Puma Biotechnology share count unchanged in Q4 2017.
  • Puma Biotechnology made up ﹤0.01% of BB&T Investment Services's portfolio in Q4 2017, its #1277 holding.
  • BB&T Investment Services first reported a position in Puma Biotechnology in Q3 2017 and has held it in 2 quarters since.
  • 203 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2017.

Based on BB&T Investment Services's 13F filing for Q4 2017, filed 15 Feb 2018.